Carotech Inc., the world’s largest and only GMP-certified tocotrienol producer will be exhibiting at the 2012 IFT Annual Meeting and Food Expo from June 25th to 28th 2012, at the Las Vegas Convention Center, Las Vegas.
Carotech will be sharing with customers and visitors the latest clinical data on its self-affirmed GRAS, patented and bioenhanced natural full-spectrum palm tocotrienol complex (Tocomin SupraBio) in neuroprotection, cardioprotection, liver health (vis-à-vis non-alcoholic fatty liver disease (NAFLD) and end stage liver disease), as well as skin nutrition (reduction of scar formation and acceleration of wound healing).
Human clinical research has recently shown that tocotrienols (Tocomin SupraBio natural full-spectrum tocotrienol complex with bioenhanced delivery system) were well absorbed and distributed to vital human tissues and organs, without being affected by the presence of alpha-tocopherol. This was the first ever tissue distribution study with tocotrienols on humans and thereby unequivocally dispelling claims that tocopherol inhibits the absorption of tocotrienols.
In another randomized, double-blind, placebo-controlled clinical trial conducted at the School of Pharmaceutical Sciences (University of Science Malaysia), human volunteers with white matter lesions were recruited into two groups and given either mixed-tocotrienols (Tocovid SupraBio – containing Tocomin SupraBio, Carotech Inc.) at 400 mg/day or placebo capsules for two years. Researchers used Magnetic resonance imaging (MRI) to compare white matter lesions volume in volunteers. White matter lesions are subclinical areas of brain damage strongly associated with established cardiovascular risk factors and is an independent risk factor for stroke.
Preliminary results of the clinical study are very encouraging. This is to date the largest clinical trial on tocotrienols and the full results are due to be published soon.
“Most recently, researchers at the Ohio State University Medical Center have announced the commencement of another two human clinical trials. One of them being the “NUTRITION” trial (Natural Tocotrienol Against Ischemic Stroke Event) which aims to study the potential of Tocomin SupraBio in reducing the risk for stroke through mitigating important stroke risk factors such as platelet function and lipid status,” says Mr. Bryan See, regional product manager, Carotech Inc.
“The other clinical trial will look at the efficacy of both Tocomin and Tocomin SupraBio in skin wound and scar healing via topical or both topical and oral supplementations. I look forward to discussing these updates with all the visitors at IFT 2012 in Las Vegas,” See added.
Carotech will be partnering with the Malaysian Palm Oil Council (MPOC) to exhibit at booth number 2938 at the 2012 IFT Annual Meeting and Food Expo, June 25th – 28th, 2012.